SAMN03290913
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518450 | — | A | 0.914 |
| 2 | BS_0Y66ZBWE | low-grade glioma | — | 0.899 |
| 3 | SRR6013517 | — | cohortA1 | 0.891 |
| 4 | MNG852 | — | — | 0.888 |
| 5 | s0102877 | — | — | 0.885 |
| 6 | SRR10899984 | — | — | 0.883 |
| 7 | SRR1334717 | GTEX | — | 0.882 |
| 8 | b98a06c6-3b43-4749-98cf-b28f4ba06845 | — | — | 0.881 |
| 9 | ea635e80-1225-4f52-a6cf-8f4c20201240 | — | — | 0.875 |
| 10 | C3N-03420 | — | cohortA1 | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |